Income statement
CAD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 9M | 1M | 1M | 182K | 2M |
| Gross Profit | 5M | -6M | -6M | -6M | -10M |
| Operating Income | -8M | -12M | -11M | -13M | -14M |
| EBITDA | -8M | -12M | -11M | -13M | -13M |
| Net Income | -8M | -12M | -11M | -13M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.01
+0.00% today
1Y Change
+400.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Reliq Health Technologies Inc. (RQHTF) is a Healthcare stock with a market cap of $50.00M and listed on OTC. The stock last traded around $0.01 and up 400.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +484.9%, EPS growth of +40.2%, a dividend yield of 0.0%. What stands out right now is revenue +484.9%, EPS +40.2%, free cash flow -13.0% with operating margin -97.4% and ROIC -124.8%. Valuation sits in the middle of the pack at price/sales 5.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RQHTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RQHTF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RQHTF Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RQHTF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.3M
+1147.6% YoY
FY Net Income
-$13.8M
-6.1% YoY
Free Cash Flow
-$8.2M
+31.9% YoY
Revenue Growth
+484.9%
EPS Growth
+40.2%
Gross Margin
62.0%
Net Margin
-95.5%
Income statement
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 9M | 1M | 1M | 182K | 2M |
| Gross Profit | 5M | -6M | -6M | -6M | -10M |
| Operating Income | -8M | -12M | -11M | -13M | -14M |
| EBITDA | -8M | -12M | -11M | -13M | -13M |
| Net Income | -8M | -12M | -11M | -13M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 133K | 226K | 13K | 345K | 10M |
| Total Assets | 10M | 3M | 3M | 4M | 12M |
| Total Liabilities | 4M | 2M | 2M | 1M | 531K |
| Shareholder Equity | 6M | 1M | 1M | 3M | 12M |
| Total Debt | 305K | 403K | 460K | 0 | 0 |
| Net Debt | 172K | 136K | 447K | -345K | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+31.9% YoY
Capital Expenditures
0
Free Cash Flow
8M
+31.9% YoY
Key ratios
Gross Margin
62.0%
Operating Margin
-97.4%
Net Margin
-95.5%
ROE
-221.6%
Debt / Equity
0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.